UAE Launches Next-Gen GPS-Less Navigation and Secure Flight Control to Strengthen Aviation Security
18.2.2025 14:19:00 CET | Business Wire | Press release
VentureOne and ADASI Partner to Integrate Advanced Autonomous Flight Technologies Powered by TII – Perceptra and Saluki Unveiled at IDEX 2025
As dual-use technologies increasingly drive economies of scale worldwide, ADASI, a leader in UAV system manufacturing, has announced their adoption of two advanced autonomous flight technologies by Abu Dhabi’s VentureOne: Perceptra, a new cutting-edge GPS-less navigation technology, and Saluki, a high-security flight control technology for autonomous systems.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250218620933/en/

UAE Launches Next-Gen GPS-Less Navigation and Secure Flight Control to Strengthen Aviation Security (Photo: AETOSWire)
These technologies, both developed by the Technology Innovation Institute, are designed to deliver secure, resilient operations in the most challenging environments. They have been optimized for UAV manufacturers, offering enhanced resilience, precision, and security for autonomous aerial operations. The agreement between VentureOne, ADASI, and TII was formalized at IDEX 2025, the Middle East’s largest defense exhibition, at which Saluki and Perceptra were unveiled.
Global Positioning System (GPS) technology has long been a fundamental pillar of navigation, supporting applications from everyday smartphone use to critical defense and military operations. However, this widespread reliance on GPS has exposed vulnerabilities that can be exploited through techniques like jamming and spoofing. Jamming occurs when signals on the same frequency overwhelm GPS receivers, preventing accurate location tracking, while spoofing involves transmitting counterfeit signals to deceive receivers into calculating incorrect positions or times. These vulnerabilities pose significant risks across sectors that depend on precise navigation, including autonomous drones, commercial aviation, and military aircraft.
In defense and security, compromised GPS signals can impact mission success and personnel safety, while in aviation, navigation errors may cause flight path deviations and operational disruptions – reports of which have the aviation industry and international regulators such as IATA and European regulator EASA seeking urgent solutions for GPS interference, according to one Reuters report in 2024.
For autonomous systems like drones and self-driving vehicles, the inability to maintain accurate positioning can create safety hazards, particularly in dynamic or high-risk environments, from aviation to defense. As the use of GPS-dependent systems continues to grow, the need for resilient, alternative navigation solutions has become increasingly critical. Perceptra and Saluki overcome many of today’s numerous challenges with advanced vision-based navigation, delivering reliable, resilient performance.
Dr. Najwa Aaraj, CEO of TII, said, “Perceptra, with its GPS-less capabilities, and Saluki, with its sophisticated Zero Trust architecture, represent a significant leap in autonomous navigation with the potential to transform multiple sectors. From supporting safe travel in commercial flights, search-and-rescue missions with precise navigation, to enabling efficient urban drone logistics for deliveries in densely populated cities, these technologies have broad real-world applications. Their adaptability also makes them invaluable in defense, ensuring secure and resilient operations in even the most challenging environments. This collaboration reflects our commitment to developing advanced, dual-use technologies that serve both civilian and defense needs while positioning the UAE as a leader in next-generation autonomous systems.”
Perceptra is a vision-based system that ensures reliable navigation without GPS, allowing aerial platforms to operate in GNSS-denied environments. It features visual relocking, low navigation errors, and easy integration across platforms for intelligence, surveillance, reconnaissance, and electronic warfare.
Saluki is a secure, high-performance flight controller and mission computer with Zero Trust architecture. With PX4 compatibility, Gen AI capabilities, and 300 TOPS compute power, it supports multi-vehicle management for mission-critical defense applications.
“At ADASI, we integrate only the most advanced, field-proven technologies to ensure our UAVs operate with unmatched precision, resilience, and security, even in the most contested environments,” said Juma Al Kaabi, the CEO of ADASI. “Perceptra and Saluki provide exactly what next-generation UAVs require: secure, GPS-independent navigation and AI-powered mission control.”
“VentureOne is dedicated to ensuring that cutting-edge research becomes reality to make a positive impact and transform industries,” said Reda Nidhakou, the Acting CEO of VentureOne. “Saluki and Perceptra are just two of many new innovations to come that will help ensure more resilient and safer drone operations in different sectors, starting with defense. We are working on a more comprehensive air autonomy and security portfolio that will play a central role in future drone operations.”
Last week, TII announced its collaboration with the General Civil Aviation Authority (GCAA) to support regulatory efforts by developing advanced methodologies for air corridor design. These methodologies aim to optimize flight routes and reduce the risk of aerial incidents in complex urban airspaces, ensuring safe and efficient navigation for both piloted and autonomous drone taxis. These efforts, alongside Perceptra and Saluki, reinforce Abu Dhabi’s vision to lead in next-generation navigation and AI-powered autonomy.
Both VentureOne and TII are part of the Advanced Technology Research Council (ATRC), which oversees Abu Dhabi’s research and development ecosystem to advance transformative technologies with global impact. ADASI is part of the EDGE Group, the advanced technology and defense conglomerate.
Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20250218620933/en/

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom